01
Open access. Candid operator feedback.
A working conversation, not a courtesy meeting.
We review your materials and provide direct, operator-level feedback on product positioning, market sizing, commercialization strategy, supply chain implications, and Asia biopharma market dynamics.
Founders walk away with specific, actionable input from a team that has actually sold into the customers they’re targeting, for nearly two decades.
Available to
Any company that reaches out.
02
Customer discovery & PMF validation.
Direct signal from real buyers, not theoretical TAM.
The operating company’s internal sales and customer success team surveys their pharma, biotech, CRO, and CDMO customers across Asia to test real demand for your product. The feedback loop is real, fast, and quantitative.
Most early-stage companies validate PMF through expert calls or small-N customer interviews. This tier gives you direct signal from a curated set of actual buyers: the same people who would write the purchase orders.
Available to
Companies whose products align with the operating company’s catalog or our investment thesis.
03
Product demos in China.
Face time with real customers in their working environments.
We bring you and your product into China for hands-on demos with end users at CDMOs and pharma companies. Direct, contextualized product feedback. Exposure to one of the world’s largest biopharma markets. Relationship seeding that compounds over time.
Reserved for companies where the founder is ready to convert a demo into a commercial conversation.
Available to
Companies with distinguished traction and demonstrable PMF.
04
Asia distribution partnership.
The operating company becomes your commercial motor in Asia.
Our operating partner can become your distribution partner across China, handling regulatory navigation, logistics and import/export infrastructure, customer relationship management, and local sales and customer success.
Building Asia distribution from scratch is one of the most expensive, time-consuming, and failure-prone challenges for a Western life-sciences tools company. The operating company shortcuts that path. You preserve capital, time, and focus to deploy on product and core-market expansion while it runs the Asia commercial motor.
Available to
Companies whose products succeed in earlier-tier validation.
40
Industrial supplier partnerships
1,000+
Bio-industry customers
The operating company holds China-exclusive agency for select international biopharma brands and is an authorized partner across 40+ supplier relationships. Customer base spans pharma, biotech, CRO, CDMO, biopharmaceutical manufacturers, in-vitro diagnostic producers, and university and research institute procurement platforms across Beijing, Shanghai, Chengdu, Guangzhou, Wuhan, and Shenzhen.
Plus Capital
We can also be your early capital partner.
In addition to the four operational tiers above, Yan Ventures is also looking to be your early capital partner. Check sizes range from $100K to $2M, typically pre-seed through Series A. Capital is deployed alongside the full operating-company infrastructure stack, so every check arrives with a commercial motor attached.
When we invest, our success and your success are tied to the same outcome: real product sales to real customers. Founders gain a long-term capital partner aligned to commercial reality, not exit timing.
Get In Touch
Send us a paragraph and we’ll tell you which tier fits.
Send a short deck or one-pager, your current fundraising status, and a brief note on what type of support is most valuable: feedback, customer validation, Asia market access, capital, or a combination.
jesse [at] yanvc [dot] com
